The FDA granted fast track designation to MCO-010 from Nanoscope Therapeutics for the treatment of retinitis pigmentosa.
The ambient light activatable multi-characteristic opsin optogenetic monotherapy is administered by intravitreal injection to patients with retinitis pigmentosa who have advanced vision loss. Topline data from the RESTORE clinical trial of MCO-010 in 27 patients with retinitis pigmentosa are expected in the first half of 2023.
In addition, Nanoscope recently completed enrollment in the phase 2 STARLIGHT clinical trial of MCO-010 in patients with advanced vision loss due to